N/A
N=190
Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)
Common Cold
Bottom Line
View on ClinicalTrials.gov: NCT01669603 ↗Enrolled (actual)
190
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcome: Primary: Interleukin-8 (IL-8) — 133; 122 pg/ml
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Bifidobacterium lactis Bl-04 (Dietary_supplement); Placebo (Dietary_supplement); Rhinovirus (Biological)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Virginia
- Primary completion
- Jun 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Interleukin-8 (IL-8) |
133; 122 | — |
Summary
The study is designed to assess the effect of ingestion of a probiotic on innate and adaptive host responses to rhinovirus infection.
Eligibility Criteria
Inclusion Criteria
AT ENROLLMENT:
- Subject must be 18-60 years of age.
- Subject must read and sign a copy of the approved Consent Form
- Female subjects must be using an effective birth control method.
INCLUSION CRITERIA AT DAY -28
- Subject must read and sign a copy of the approved Consent Form
AT CHALLENGE:
- Female subjects must be using an effective birth control method.
- Subject must have a serum neutralizing antibody titer of less than or equal to 1:4 to rhinovirus type 39
Exclusion Criteria
AT ENROLLMENT:
- Current cancer diagnosis or immunosuppressive therapy in the last 6 months
- Any clinically significant abnormalities of the upper respiratory tract
- Any clinically significant acute or chronic respiratory illness
- Any clinically significant bleeding tendency by history
- Hypertension that requires treatment with antihypertensive medications
- History of angina or other clinically significant cardiac disease
- Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study
- History of regular use (more than 3 days in 7) of tobacco products within the preceding two weeks
- History of drug or alcohol abuse in the 6 months preceding the study
EXCLUSION CRITERIA AT DAY -28
- Antibiotic use within 3 months prior to study start
- Female subjects with a positive urine pregnancy screen.
- History of use of probiotics in the preceding 2 weeks.
EXCLUSION CRITERIA AT CHALLENGE:
- Any upper respiratory infection or allergic rhinitis in the two weeks prior to the start of the study
- Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study
- Use of any anti-inflammatory (steroids or NSAIDs) or cough/cold preparation in the two weeks prior to the study
Data sourced from ClinicalTrials.gov (NCT01669603). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.